Molecular chaperone therapy

Molecular chaperone therapy
Results: 2

#	Item
1	Amicus Therapeutics Announces Positive Results From Two Phase 1 Clinical Studies of AT2220 for Pompe Disease CRANBURY, N.J., October 23, [removed]Amicus Therapeutics, a biopharmaceutical company developing small molecule, Add to Reading List Source URL: www.unitedpompe.com Language: English - Date: 2007-10-23 11:26:48 Science Clinical research Design of experiments Glycogen storage disease type II Hepatology Clinical trial Molecular chaperone therapy Health Medicine Lysosomal storage diseases
2	Amicus Therapeutics Begins Phase 2 Clinical Trial of AT2220 in Pompe Disease CRANBURY, N.J., June 3, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Amicus Therapeutics (Nasdaq: FOLD), a biopharmaceutical company Add to Reading List Source URL: www.unitedpompe.com Language: English - Date: 2008-06-03 09:27:22 Lysosomal storage diseases Glycogen storage disease type II Hepatology Motor neurone disease Acid alpha-glucosidase Amyotrophic lateral sclerosis Clinical trial Molecular chaperone therapy Health Rare diseases Medicine